(NASDAQ: TERN) Terns Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 25.97%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 41.35%.
Terns Pharmaceuticals's earnings in 2025 is -$91,745,000.On average, 14 Wall Street analysts forecast TERN's earnings for 2025 to be -$100,550,194, with the lowest TERN earnings forecast at -$107,201,034, and the highest TERN earnings forecast at -$97,399,796. On average, 13 Wall Street analysts forecast TERN's earnings for 2026 to be -$119,680,109, with the lowest TERN earnings forecast at -$140,647,756, and the highest TERN earnings forecast at -$103,831,858.
In 2027, TERN is forecast to generate -$138,915,038 in earnings, with the lowest earnings forecast at -$158,657,530 and the highest earnings forecast at -$124,965,777.